Top Companies in Cancer Profiling Market by Size, Share, Historical and Future Data & CAGR | Report by Vantage Market Research
Cancer Profiling Market is projected to reach a value of USD 19.2 Billion by 2030 at a CAGR of 10.8% over the forecast period 2023-2030.
Vantage Market Research has recently published a new report on the "Cancer Profiling Market” Global Industry Assessment & Forecast to identify key trends and challenges. The report offers insights into the competitive landscape, prospects, and key investment considerations for businesses operating in the Cancer Profiling market. The key statistics in the report highlight that Global Cancer Profiling Market was valued at USD 9.4 Billion in 2022 and is projected to reach a value of USD 19.2 Billion by 2030 at a CAGR of 10.8% over the forecast period 2023-2030. The global Cancer Profiling market will continue expanding due to rising demand from different sectors, including mass spectrometry, microarrays, genomic biomarker, etc.
Request Sample Report of Cancer Profiling Market @ https://www.vantagemarketresearch.com/cancer-profiling-market-2101/request-sample
The Global Cancer Profiling market is dominated by well-known players like QIAGEN N.V.(Germany), HTG Molecular Diagnostics Inc. (U.S.), Illumina Inc.(U.S.), Sysmex Corporation (Japan), NanoString Technologies Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Tempus Labs, Predective Oncology Inc. (U.S.), Guardant Health Inc. (U.S.), NeoGenomics Inc. (U.S.), F. Hoffman-La Roche Ltd. (U.S.), to name a few. These market participants also pursue strategies like investments, partnerships, acquisitions, and mergers to increase their market dominance. Furthermore, businesses are investing in the creation of better services. They are also concentrating on keeping their prices reasonable.
Let’s Take a Look at the Top Market Players that are Captivating the Cancer Profiling Market
- QIAGEN N.V. (Germany)
QIAGEN N.V. provides molecular sample insights into samples of tissue, fluids, etc. are collected by using sample technologies and this, technology stabilizes, extracts, and purifies various molecules of interest, such as DNA, RNA, OR proteins from other cellular components.
- HTG Molecular Diagnostics, Inc. (U.S.)
HTG's mission is to advance the promise of precision medicine through innovative transcriptional comprehensive profiling technology designed to accelerate diagnostic development and accelerate the discovery of new drug candidates for life-changing outcomes.
- Illumina, Inc. (U.S.)
Illumina develops, manufactures, and markets integrated systems to analyze genetic variation and biological function. Illumina, Inc., offers a variety of products and services for sequencing, genotyping, gene expression, and proteomics. Illumina's technology reportedly brought the cost of sequencing the human genome to $1,000 by 2014. Its customers include genomics research centres, biotechnology companies pharmaceutical companies, academic institutions and clinical research organizations.
- Sysmex Corporation (Japan)
Sysmex, together with its subsidiaries, develops, manufactures, and sells laboratory test reagents and equipment; develop and sale of computer systems for medical institutions and the development and sells software used for clinical research information systems. In addition, Sysmex also sells extracorporeal diagnostic agents and imports and sells medical devices through its subsidiary. The company distributes its products to domestic markets and overseas, including the United States, Germany, the United Kingdom, China, and Singapore.
- NanoString Technologies Inc. (U.S.)
The research tools of NanoString Technologies Inc., are based on the nCounter Analysis System, a modification of DNA microarray technology. The nCounter system enables the simultaneous profiling of hundreds of genes, proteins, miRNAs, or copy number variants with high sensitivity and precision using molecular barcodes and microscopic imaging in the hybridization reaction. To enable spatial transcriptomics and proteomics from a single FFPE slide, NanoString launched the GeoMx Digital Spatial Profiler in 2019. The GeoMx DSP combines whole-tissue imaging with gene expression and protein data to enable single-cell resolution in a spatial context.
- Thermo Fisher Scientific Inc. (U.S.)
Thermo Fisher Scientific Inc (Thermo Fisher) is a provider of medical devices, analytical instruments, reagents and consumables, software, and services that address complex analytical challenges in research, diagnostics, and clinical laboratories.
- Tempus Labs Inc. (U.S.)
Tempus Labs Inc offers comprehensive genomic testing (DNA, RNA, etc.). These next-generation sequencing tests can be performed to identify specific changes that may cause cancer behaviour. This information can help your doctor optimize your treatment plan based on your unique cancer.
- Predective Oncology, Inc. (U.S.)
Predictive oncology is changing the landscape of cancer drug development and enabling the development of more effective therapies in cancer treatment.
- Guardant Health Inc. (U.S.)
Guardant Health Inc. is dedicated to helping patients at all stages of cancer live longer and healthier lives through blood tests and the information they provide. Their FDA-approved test helps guide treatment decisions for patients with advanced cancer.
- NeoGenomics, Inc., (U.S.)
NeoGenomics is a leading cancer diagnostic, medicines, and information services company serving oncologists, pathologists, pharmaceutical companies, and academic centres in their efforts to provide a better future for cancer patients.
- F Hoffman-La Roche Ltd. (Switzerland)
F Hoffmann-La Roche Ltd (Roche) is a biotechnology company that develops medicines and diagnostics for the treatment of serious diseases. It offers drugs to treat cancer, other autoimmune diseases, central nervous system disorders, eye diseases, infectious diseases, and respiratory diseases.
Read Our Latest Blog: Top Companies in Breathable Films Market
Do You Have Any Queries or Specific Requirements? You may enquire to our sales team before purchasing.
6218 Georgia Avenue NW Ste 1 - 564
Washington DC 20011-5125
United States Tel: +1 202 380 9727
Email: [email protected]
Website: Vantage Market Research